LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

MannKind Corp

Suletud

SektorTervishoid

3.77 -1.31

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.72

Max

3.85

Põhinäitajad

By Trading Economics

Sissetulek

5.7M

13M

Müük

1.6M

78M

P/E

Sektori keskmine

37.95

50.291

Aktsiakasum

0.04

Kasumimarginaal

16.793

Töötajad

403

EBITDA

8.3M

27M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+154.55% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-354M

1.2B

Eelmine avamishind

5.08

Eelmine sulgemishind

3.77

Uudiste sentiment

By Acuity

13%

87%

18 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

MannKind Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. juuni 2025, 23:49 UTC

Tulu

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26. juuni 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26. juuni 2025, 21:30 UTC

Tulu

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26. juuni 2025, 21:07 UTC

Tulu

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26. juuni 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26. juuni 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26. juuni 2025, 23:34 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26. juuni 2025, 23:33 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26. juuni 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers Will No Longer Receive Earnings From BWP Management

26. juuni 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26. juuni 2025, 23:31 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26. juuni 2025, 23:31 UTC

Omandamised, ülevõtmised, äriostud

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26. juuni 2025, 23:30 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26. juuni 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26. juuni 2025, 23:19 UTC

Omandamised, ülevõtmised, äriostud

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26. juuni 2025, 22:06 UTC

Tulu

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. juuni 2025, 21:15 UTC

Tulu

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26. juuni 2025, 21:07 UTC

Tulu

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. juuni 2025, 21:06 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26. juuni 2025, 21:06 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26. juuni 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26. juuni 2025, 21:05 UTC

Omandamised, ülevõtmised, äriostud

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. juuni 2025, 21:05 UTC

Omandamised, ülevõtmised, äriostud

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. juuni 2025, 20:52 UTC

Tulu

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26. juuni 2025, 20:51 UTC

Tulu

Correct: Nike 4Q Net $211M, Not $200M >NKE

26. juuni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. juuni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

MannKind Corp Prognoos

Hinnasiht

By TipRanks

154.55% tõus

12 kuu keskmine prognoos

Keskmine 9.8 USD  154.55%

Kõrge 12 USD

Madal 7 USD

Põhineb 5 Wall Streeti analüütiku instrumendi MannKind Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

5

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

4.079 / 4.323Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

18 / 380 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.